Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
Authors
Keywords
-
Journal
LEUKEMIA
Volume 27, Issue 4, Pages 823-828
Publisher
Springer Nature
Online
2012-09-27
DOI
10.1038/leu.2012.274
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
- (2012) J. R. Mikhael et al. BLOOD
- Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
- (2012) C. P. Venner et al. BLOOD
- Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
- (2012) Shaji Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
- (2011) D. E. Reece et al. BLOOD
- Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study
- (2011) V. Sanchorawala et al. HAEMATOLOGICA
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy
- (2011) A. D. Cohen et al. Hematology-American Society of Hematology Education Program
- Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
- (2010) S. Bringhen et al. BLOOD
- Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006
- (2010) M A Gertz et al. BONE MARROW TRANSPLANTATION
- A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study
- (2010) S. Lonial et al. CLINICAL CANCER RESEARCH
- Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
- (2010) Karl Bodin et al. NATURE
- How I treat amyloidosis
- (2009) R. L. Comenzo BLOOD
- A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
- (2009) O. A. O'Connor et al. CLINICAL CANCER RESEARCH
- Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego)
- (2007) Angela Dispenzieri et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started